Speaking at a public forum in Kuala Lumpur in 2023, a senior officer from Ministry of Health’s (MOH) planning division ...

Articles ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Apart from simple diagnosis, the study takes an important step toward predictive health monitoring by modeling the risk of ...

Biocon bagged US FDA's approval for Kristy, which is a rapid-acting human insulin analog, indicated to improve glycemic control in patients with diabetes mellitus.

Dietitians Australia continues to urge the Federal Government to enable funding for Australians at risk of chronic diseases, ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE ...

Symptoms of hyperglycemia (high blood glucose) can include increased thirst, hunger, urination, and fatigue. Some symptoms ...

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

Prediabetes is associated with a nearly 4-fold higher risk of MASLD. (1) Approximately 33% of Indian adults have prediabetes.

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...